Intas Pharmaceuticals Ltd launched TOFATAS –a Drugs Controller General of India (DCGI) -approved, Tofacitinib Ointment 2% w/w for the treatment of mild to moderate AD in patients 18 years and above experiencing flare-ups of the disease.

Intas Pharmaceuticals Ltd launched TOFATAS –a Drugs Controller General of India (DCGI) -approved, Tofacitinib Ointment 2% w/w for the treatment of mild to moderate Atopic Dermatitis (AD) in patients 18 years and above experiencing flare-ups of the disease.

"There have been no approved Topical JAK inhibitors in India available to date and the approval of TOFATAS OINTMENT 2%, therefore, would help in patients who desire a steroid-free topical agent for Atopic Dermatitis, and we hope that real-world data mirrors the approvals given to this agent in India," says Dr Kabir Sardana, MD, DNB, MNAMS, Professor (Dermatology) at the RML Hospital, Delhi.

"Atopic Dermatitis is a chronic relapsing condition leading to poor quality of life and psychosocial complications. Current therapy has unmet needs. We welcome the DCGI-approved new topical Tofacitinib 2%, which will give new hope to these sufferers," says Dr Satish Udare, Senior Consultant Dermatologist, Thane/Navi Mumbai, in a news release.

Dr Alok Chaturvedi, Associate Executive Vice President & Head-Medical Affairs, Intas,  adds,  "Intas being a frontrunner in dermatology therapy, boldly and successfully endeavoured to bridge this critical treatment gap by investing in extensive research efforts to develop and formulate TOFATAS Ointment - a drug that delivers the desired outcome and the clinical benefits for Atopic Dermatitis patients. A Phase III clinical study of TOFATAS (Tofacitinib Ointment 2% w/w) in Atopic Dermatitis patients in India showed remarkable safety and efficacy."